External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology EAU 2024
Roche and Genentech at

EAU 2024

April 05 - April 08
Paris, France
eau.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Apr 5 / Roche and Genentech
Clinical outcomes in patients with high-risk, post-cystectomy MIBC with persistent circulating tumour DNA-negative status on serial testing: surveillance analysis from the IMvigor011 study
This poster reports data from the surveillance cohort of patients with high-risk MIBC from the global phase III IMvigor011 study. Clinical outcomes in patients who remained ctDNA negative following cystectomy based on serial ctDNA testing are included in the analysis.
Oncology Urothelial Cell Carcinoma EAU-2024
09:05 AM
Duration 5mins Purple Area, eURO Auditorium 2
Clinical outcomes in patients with high-risk, post-cystectomy MIBC with persistent circulating tumour DNA-negative status on serial testing: surveillance analysis from the IMvigor011 study
Thomas Powles
Oncology | Urothelial Cell Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.